LENZ Therapeutics financials
$3.86−2.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $19.1M | $0.00 |
| Gross profit | $18.7M | $0.00 |
| Gross margin | 97.8% | — |
| Operating income | -$91.1M | -$58.6M |
| Net income | -$82.1M | -$49.6M |
| Net margin | −430.0% | — |
| Diluted EPS | $-2.85 | $-2.34 |
| EBITDA | -$90.9M | -$58.6M |
| Operating cash flow | -$69.2M | -$59.4M |
| Free cash flow | -$70.0M | -$59.9M |
| Diluted shares | 28.8M | 21.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $25.2M | $20.2M |
| Short-term investments | $267.2M | $188.9M |
| Total debt | $0.00 | $0.00 |
| Total assets | $305.9M | $215.3M |
| Total liabilities | $21.5M | $11.2M |
| Shareholders' equity | $284.3M | $204.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology